Company: MYGN
Filing Date: 2025-11-04
Form Type: 10-Q
Source: 0000899923-25-000112
Chunk: 42

Company: MYRIAD GENETICS INC
Filing Date: 2025-11-04
Form: 10-Q
Item: Part I, Item 1
Chunk 42
---
 growth by leveraging our expanded prenatal offerings, including FirstGene Multiple Prenatal Screen, to drive increased volume. We also plan to focus on high value GeneSight accounts and leverage state biomarker laws to improve our reimbursement rates. Third, we plan to complement the revenue growth drivers outlined above with an enhanced focus and commitment on delivering sustained, profitable growth.  By maintaining financial discipline, growing revenue faster than operating expenses, and strengthening our planning and execution capabilities, we believe we can increase our profitability while delivering sustained revenue growth.

22

Business Updates

Our recent significant business updates include the following: 

•In October 2025, we announced the addition of two genes, F8 and FXN, to the Foresight Carrier Screen Universal Plus Panel.

•In September 2025, we announced a strategic collaboration with SOPHiA Genetics, Inc. to develop and provide pharmaceutical companies with an innovative global liquid biopsy companion diagnostic (CDx) test.

•In September 2025, we announced the publication of a new meta-analysis of six prospective controlled studies that included 3,532 adults with major depressive disorder (MDD). The meta-analysis showed that when GeneSight Psychotropic test results were available to treating clinicians, there were significant improvements in response and remission rates for patients with MDD, compared to treatment as usual.

•Effective August 16, 2025, Benjamin R. Wheeler was appointed Chief Financial Officer. 

Results of Operations for the Three Months Ended September 30, 2025 and 2024

The results of operations for the three months ended September 30, 2025 and 2024 are discussed below.  

Revenue

The following table summarizes year-over-year revenue changes in our core product categories:

Three months ended September 30,% of Total Revenue(in millions)20252024Change20252024Hereditary Cancer$93.0 $90.5 $2.5 45%43%Tumor Profiling29.5 31.6 (2.1)14%15%Prenatal44.5 43.5 1.0 22%20%Pharmacogenomics38.7 47.7 (9.0)19%22%Total revenue$205.7 $213.3 $(7.6)100%100%

The following table summarizes volume changes in our core product categories:

Three months ended September 30,(in thousands)20252024% ChangeVolume:Hereditary Cancer82 74